| __timestamp | Arrowhead Pharmaceuticals, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 175000 | 751040000 |
| Thursday, January 1, 2015 | 382000 | 889895000 |
| Friday, January 1, 2016 | 158333 | 1116854000 |
| Sunday, January 1, 2017 | 31407709 | 1313646000 |
| Monday, January 1, 2018 | 16142321 | 1491212000 |
| Tuesday, January 1, 2019 | 168795577 | 1704048000 |
| Wednesday, January 1, 2020 | 87992066 | 1860455000 |
| Friday, January 1, 2021 | 138287000 | 1846275000 |
| Saturday, January 1, 2022 | 243231000 | 2096039000 |
| Sunday, January 1, 2023 | 240735000 | 2419226000 |
| Monday, January 1, 2024 | 3551000 | 2853915000 |
Infusing magic into the data realm
In the dynamic world of biotechnology, understanding revenue trends is crucial for investors and stakeholders. BioMarin Pharmaceutical Inc. and Arrowhead Pharmaceuticals, Inc. have shown distinct revenue trajectories over the past decade. BioMarin, a leader in rare disease therapies, has seen its revenue grow steadily, peaking at approximately $2.4 billion in 2023, marking a 222% increase since 2014. In contrast, Arrowhead, known for its RNA interference therapies, experienced a more volatile revenue path, with a significant surge in 2022, reaching around $243 million, a remarkable 138,000% increase from its 2014 figures. However, 2024 data for BioMarin is missing, indicating potential reporting delays or strategic shifts. This comparison highlights the diverse growth strategies and market responses within the biotech sector, offering valuable insights for future investment decisions.
Merck & Co., Inc. vs Arrowhead Pharmaceuticals, Inc.: Examining Key Revenue Metrics
Bristol-Myers Squibb Company or BioMarin Pharmaceutical Inc.: Who Leads in Yearly Revenue?
Revenue Showdown: Alnylam Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.
Annual Revenue Comparison: Biogen Inc. vs BioMarin Pharmaceutical Inc.
Genmab A/S and Arrowhead Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis
Who Generates More Revenue? Bio-Techne Corporation or BioMarin Pharmaceutical Inc.
Comparing Revenue Performance: BioMarin Pharmaceutical Inc. or Veracyte, Inc.?
BioMarin Pharmaceutical Inc. and Xencor, Inc.: A Comprehensive Revenue Analysis
BioMarin Pharmaceutical Inc. and MiMedx Group, Inc.: A Comprehensive Revenue Analysis
Catalent, Inc. and Arrowhead Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis
Revenue Insights: Ascendis Pharma A/S and Arrowhead Pharmaceuticals, Inc. Performance Compared
Breaking Down Revenue Trends: Halozyme Therapeutics, Inc. vs Arrowhead Pharmaceuticals, Inc.